One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Akari Therapeutics, Plc
AKTX · NCM · Healthcare · Biotechnology
Current price
$8.54
52-week range
$3.02 - $39.64
Market cap
$19.52M
Balance sheet
Healthy
-12.74x Concerning
Net cash $7.00M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Akari Therapeutics, Plc
Akari Therapeutics, Plc is developing a new type of cancer treatment called antibody-drug conjugates (ADCs) which are like guided missiles for cancer cells. These ADCs deliver a powerful toxin directly to cancer cells, aiming to kill them while sparing healthy ones. The company's main focus is on its lead treatment candidate, AKTX-101, which is in early development and targets various solid tumors like lung and breast cancer.
How the company got here
Akari Therapeutics, Plc was founded in 2004 and is an oncology biotechnology company. It focuses on developing next-generation antibody-drug conjugates (ADCs), which are therapies designed to deliver cancer-killing toxins directly to tumor cells. The company's core innovation lies in its proprietary payload, PH1, which is designed to disrupt cancer cell function and trigger an immune response. This approach aims to create more effective and targeted cancer treatments.
What it actually does
Akari Therapeutics develops advanced cancer treatments using a technology called antibody-drug conjugates (ADCs). Think of an ADC as a guided missile for cancer. It consists of an antibody that specifically targets a protein on the surface of cancer cells, a potent drug (the 'payload') that kills cancer cells, and a linker that connects the two. Once the antibody attaches to the cancer cell, the ADC is absorbed, releasing the drug inside the cell to destroy it. Akari's unique approach uses a novel payload called PH1, which works by interfering with the cancer cell's machinery for creating proteins, leading to cell death and also stimulating the body's own immune system to fight the cancer.
AKTX-101
AKTX-101 is Akari Therapeutics's lead product candidate, currently in the preclinical stage of development. This therapy is an antibody-drug conjugate (ADC) designed to target the Trop2 receptor, a protein commonly found on the surface of various solid tumor cancer cells, including those in the lung, breast, colon, and prostate. By combining the Trop2-targeting antibody with its proprietary PH1 payload, AKTX-101 aims to deliver the cancer-killing agent directly to the tumor with minimal impact on healthy cells. The company is actively working on the necessary studies to begin human trials for AKTX-101, with a goal of starting a Phase 1 clinical trial by mid-2027.
AKTX-102
AKTX-102 is another antibody-drug conjugate (ADC) being developed by Akari Therapeutics. This candidate is designed to target CEACAM5, a protein that is present on several types of solid tumors, particularly those in the gastrointestinal tract and lungs. Similar to AKTX-101, AKTX-102 utilizes Akari's unique PH1 payload, which disrupts cancer cell function and activates the immune system. The development of AKTX-102 represents an expansion of Akari's pipeline, aiming to leverage its PH1 payload technology against a different, yet significant, cancer target.
What management is betting on now
Akari Therapeutics's current strategy is centered on advancing its lead product candidate, AKTX-101, into human clinical trials, with a Phase 1 study anticipated to begin in mid-2027. This involves completing crucial manufacturing and development work, known as IND-enabling activities, to ensure the therapy is safe and ready for testing in people. Management is also focused on expanding the utility of their proprietary PH1 payload through strategic collaborations, such as one exploring dual-payload ADCs. These efforts aim to validate their innovative approach to cancer treatment and position the company for future growth and potential partnerships.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-4.81M
Diluted EPS
0.00
Operating cash flow
$-3.11M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-14.46M
Diluted EPS
0.00
Operating cash flow
$-2.49M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-5.30M
Diluted EPS
0.00
Operating cash flow
$-3.04M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-6.40M
Diluted EPS
0.00
Operating cash flow
$-2.12M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-1.90M
Diluted EPS
0.00
Operating cash flow
$-3.26M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.71M
Diluted EPS
0.00
Operating cash flow
$-2.15M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.77M
Diluted EPS
0.00
Operating cash flow
$-2.12M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.90M
Diluted EPS
0.00
Operating cash flow
$-1.49M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $8.54
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $7.0M - more cash than debt. Interest coverage -12.7x.
Net debt
$-7.00M
Interest coverage
-12.74x
Akari Therapeutics, Plc's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
AKTX
BASELINE
Akari Therapeutics, Plc
Total debt $693.00K Interest coverage -12.74x This is the baseline the peer rows are being compared against.
Total debt $6.70M Interest coverage -111.88x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -15.63x Neither company has much profit cushion over interest right now.
Total debt — Interest coverage -48.18x Neither company has much profit cushion over interest right now.
What you should know
The case for and against AKTX
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -140.1% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.99x
P/B
0.80x
P/S
—
EV/EBITDA
—
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-140.1%
ROA
-19.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.04x
Current ratio
0.60x
Quick ratio
0.55x
Total debt
$693.00K
Total cash
$7.69M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
0.00
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-10.76M
Free CF TTM
$-10.57M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—